Newamsterdam Pharma Company N.V. (NAMS)

Apr 4, 2025, 4:01 PM EDT - 21 days ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 8:00 AM EDT - 25 days ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 11:26 PM EST - 7 weeks ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 10:48 AM EST - 2 months ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 26, 2025, 8:00 AM EST - 2 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 8:00 AM EST - 2 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Dec 13, 2024, 5:16 PM EST - 4 months ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 4 months ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 1:33 PM EST - 4 months ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 6:55 AM EST - 4 months ago

Top 3 Health Care Stocks That May Collapse This Quarter

ADPT FNA

Dec 10, 2024, 4:34 PM EST - 4 months ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 11:14 AM EST - 4 months ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 7:00 AM EST - 4 months ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 18, 2024, 3:20 PM EST - 5 months ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Oct 28, 2024, 4:30 PM EDT - 6 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 4, 2024, 12:09 PM EDT - 7 months ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Aug 30, 2024, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 1:33 PM EDT - 8 months ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Jul 26, 2024, 4:01 PM EDT - 9 months ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 5, 2024, 1:40 PM EDT - 10 months ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

May 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

Apr 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 1 year ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Feb 28, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 13, 2024, 10:40 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 1, 2024, 4:01 PM EST - 1 year ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 4, 2024, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces 2024 Strategic Priorities

Nov 13, 2023, 8:00 AM EST - 1 year ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

Oct 23, 2023, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

Oct 17, 2023, 3:00 AM EDT - 1 year ago

Tessellate BIO Emerges from Stealth

REPL

Oct 2, 2023, 9:26 PM EDT - 1 year ago

NewAmsterdam Pharma's Pioneering Pulse On Alzheimer's Breakthroughs

Sep 21, 2023, 7:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer's Disease Who Carry an ApoE4 Mutation

Sep 20, 2023, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 19, 2023, 1:10 PM EDT - 1 year ago

NewAmsterdam Pharma: Best Cardiovascular Biotech In 2023

Aug 14, 2023, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

Aug 7, 2023, 7:15 AM EDT - 1 year ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights

Jul 25, 2023, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease

Jun 9, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

Jun 6, 2023, 11:25 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares

Jun 6, 2023, 4:01 PM EDT - 2 years ago

NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares

Jun 5, 2023, 7:00 AM EDT - 2 years ago

NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients

Jun 3, 2023, 12:15 PM EDT - 2 years ago

NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

May 23, 2023, 8:00 AM EDT - 2 years ago

NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023

May 15, 2023, 1:00 AM EDT - 2 years ago

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

REPL

May 8, 2023, 8:00 AM EDT - 2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights